Cover Image
市場調查報告書

美國處方藥改列成藥市場

The US Market for Rx to OTC Switches, 7th Edition

出版商 Kalorama Information 商品編碼 260317
出版日期 內容資訊 英文 200 Pages
訂單完成後即時交付
價格
Back to Top
美國處方藥改列成藥市場 The US Market for Rx to OTC Switches, 7th Edition
出版日期: 2015年02月02日 內容資訊: 英文 200 Pages
簡介

美國的處方藥改列成藥市場達78億美元規模。主要是因為專利到期、藥品市場競爭激烈、品牌改革、消費者需求與降低成本策略。

本報告提供美國的處方藥改列成藥市場相關資料症狀、目的分別加以調查分析,OTC化的產品、成分及OTC化的預計產品概要,市場規模實際成果預測,競爭分析,各種市場影響因素分析,並彙整主要企業簡介等,為您概述為以下內容。

摘要整理

  • 調查範圍與調查方法
  • 市場規模與市場成長
  • 處方藥改列成藥影響市場的課題與趨勢
  • 主要企業

OTC藥品產業

  • OTC市場概要
  • 處方藥改列成藥市場發展
  • 美國藥品規範
  • 非處方藥安全使用規範擴大 (NSURE)
  • 美國人口統計與非處方藥市場
  • 處方藥改列成藥國際動向

過敏、咳嗽、感冒、鼻竇炎等醫藥品

  • 概要
    • 抗組織胺劑
    • 解充血劑
    • 止咳藥
    • 眼藥
    • 其他過敏藥劑
  • 症狀
    • 過敏性鼻炎
    • 感冒
    • 鼻竇炎
    • 蕁麻疹
    • 眼睛過敏
  • 產品分析
    • OTC產品
    • 近年OTC成藥活動
    • 今後預計OTC化的處方藥
  • 市場分析
  • 市場規模、預測
  • 競爭分析
  • 止痛藥物
  • 概要
  • 症狀
  • 產品分析
    • OTC成分
    • 今後預計OTC化的處方藥
  • 市場分析
    • 市場規模實績、預測
    • 競爭分析

抗感染劑

  • 概要
  • 症狀
  • 產品分析
    • OTC化成分
    • 今後預計OTC化的處方藥
  • 市場分析
    • 市場規模實績、預測
    • 競爭分析

胃腸藥

  • 概要
  • 症狀
  • 產品分析
  • OTC化成分
  • 今後預計OTC化的處方藥
  • 市場分析
    • 市場規模實績、預測
    • 競爭分析

禁煙相關

  • 概要
  • 症狀
  • 產品分析
    • OTC化成分
    • 今後預計OTC化的處方藥
  • 市場分析
    • 市場規模實績、預測
    • 競爭分析

其他藥劑分類

整體市場:摘要

  • 概要
  • 整體市場規模、預測
  • 美國轉類預測
  • 市場:區分分類
  • 競爭分析
  • 主要處方藥轉成藥市場企業檔案
  • 持續讓產品成長的策略
  • M&A
  • 同步行銷:處方藥vs. OTC
  • 對處方藥製造商的影響
  • 直銷廣告
  • 專利到期
  • Bayer
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Perrigo Company
  • Pfizer
  • Prestige Brands
  • Procter & Gamble
  • Reckitt Benckiser
  • Sanofi/Chattem

企業名錄

圖表列表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: KLI5459601

Over the past 38 years the U.S. Rx-to-OTC market has grown into a $7.8 billion market. This has mainly been due to factors such as patent expirations, increasing competitiveness with the pharmaceutical environment, brand re-invention, consumer demand, and cost containment strategies. The U.S. market for Rx-to-OTC Switches encompasses a wide variety of products that have been determined safe and effective as over-the-counter products, once only available by prescription.

The current climate of patient-consumer awareness of health issues is continuing to influence the Rx-to-OTC market. Consumers are more prepared to take responsibility for their own health and are willing to purchase medicines over the counter. An increased focus on cost-savings, coupled with the effects of advertising and promotion, result a higher rate of OTC purchases. Aging baby boomers, many of which are taking greater interest in their health, have created a growing Rx-to-OTC industry in America. It is anticipated that Rx-to-OTC switch products will continue to grow as interest from both consumers and developers continue to expand.

The U.S. Market for Rx-to-OTC Switches focuses on several treatment segments in which Rx-to-OTC switches are available. These include:

  • Allergy, Cough, Cold, and Sinus Products
  • Analgesics, NSAIDs, and Pain Treatments
  • Anti-Infectives
  • Gastrointestinal Drugs
  • Hair Loss Products
  • Hormones
  • Oral Care
  • Overactive Bladder
  • Rectal Ointments
  • Sleep-aids
  • Smoking Cessation
  • Weight Loss

In addition to the areas with switches in place, Kalorama Information has identified other areas which may be open to Rx-to-OTC switches in the future. These include:

  • Blood Products
  • BPH Treatments
  • Cholesterol-reducing Drugs
  • Hormone Replacement Therapies
  • Migraine Treatments
  • Opioid Overdose Treatment
  • Osteoporosis Treatments
  • Sexual Dysfunction/ Erectile Dysfunction

The report covers OTC drugs that were once only available by prescription due to either the active ingredient or dosage of the drug. Current and historical revenues for product segments include both the switched brands and OTC drugs containing switched ingredients. Forecasted data includes current products and forecasted switches which are outlined in the report.

The report includes statistical information for conditions and diseases affecting the U.S. population, including detail discussions, tables and figures. Each segment provides an overview, descriptions of products on the market, market estimates and forecasts, and competitive analysis of leading providers. In addition to above-mentioned information, the report includes current issues and trends affecting the industry and identifies trends that may arise in the future.

Table of Contents

EXECUTIVE SUMMARY

  • Overview
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting the Rx-to-OTC Switches Market
  • Leading Participants

THE OTC DRUG INDUSTRY

  • Overview of the Over-the-Counter Drug Market
    • Distribution Channels
    • Retail Market Value OTC Drug Industry
  • Development of the Rx-to-OTC Drug Market
  • U.S. Drug Regulation
    • Expanding Drug Access with Behind the Counter Status
  • Nonprescription Drug Safe Use Regulatory Expansion (NSURE)
    • Physician Uncertainty in Increasing Nonprescription Drug Access
    • Pharmacists Generally Favor Self-Medication
    • Online Resources for Health Information and Drug Selection
      • Social Media's Influence on Consumer Health Products
  • U.S. Demographics and the Non-Prescription Drug Market
    • U.S. Population over 65
    • U.S. Health Spending Indicators
  • International Trends in Rx-to-OTC Switches

ALLERGY, COUGH, COLD, AND SINUS PRODUCTS

  • Overview
    • Antihistamines
    • Decongestants
    • Cough Preparations
    • Ophthalmic Preparations
    • Other Allergy Preparations
      • Mast Cell Stabilizers
      • Intranasal Steroids
  • Description of Conditions
    • Allergic Rhinitis
    • Common Cold
    • Sinusitis
    • Hives
    • Ocular Allergies
  • Product Analysis
    • Switched Products
      • Antihistamines
      • Decongestants
      • Cough Preparations
      • Ophthalmic Preparations
      • Other Allergy Preparations
    • Recent Switch Activity
      • Flonase Allergy
      • Nasacort Allergy
    • Prescription Products with Anticipated OTC Approvals
      • Astelin Nasal Spray
      • Beconase AQ
      • Rhinocort
      • Clarinex
      • Xyzal
      • Atrovent Nasal Spray
      • Nasonex
      • Singulair
  • Market Analysis
  • Market Size and Forecast
  • Competitive Analysis

ANALGESICS AND OTHER PAIN RELIEVERS

  • Overview
    • Analgesics
    • Nonsteroidal Anti-inflammatory Drugs
    • Topical Pain Relievers and Other Similar Products
  • Description of Conditions
    • Pain
    • Inflammation
  • Product Analysis
    • Switched Products
      • Antipruritic
      • Internal analgesic/antipyretic
      • Oral Anesthetic
    • Prescription Products with Anticipated OTC Approvals
      • Nonsteroidal anti-inflammatory drugs
        • Voltaren (diclofenac)
        • Diflunisal
        • Etodolac
        • Nabumetone
        • Feldene (piroxicam)
      • Migraine Treatments
        • Axert
        • Imitrex
        • Maxalt
        • Zomig
        • Other Migraine Treatments
        • Market Analysis
        • Market Size and Forecast
        • Competitive Analysis

ANTI-INFECTIVES

  • Overview
    • Antibiotics
    • Antifungals
    • Antivirals
    • Antiparasitics
  • Description of Conditions
    • Vaginal Infections
    • Athlete's Foot
    • Jock Itch
    • Ringworm
    • Dandruff
    • Scabies and Pediculosis
    • Pinworm
    • Fungal Nail Infections
  • Product Analysis
    • Switched Products
      • Antifungals
      • Anthelmintics
      • Antimicrobials
      • Pediculicides
    • Prescription Products with Anticipated OTC Approvals
      • Antivirals
        • Zovirax
        • Valtrex
        • Denavir
        • Famvir
        • Influenza Antivirals
      • Antibiotics
        • Antibiotic Public Health Preparedness
      • Antifungals
    • Market Analysis
      • Market Size and Forecast
      • Competitive Analysis

GASTROINTESTINAL DRUGS

  • Overview
  • Description of Conditions
    • Nausea
    • Diarrhea
    • Constipation
    • Heartburn
    • Acid reflux
  • Product Analysis
    • Switched Products
      • Histamine H2 Inhibitors
      • Proton Pump Inhibitors
      • Antidiarrheals
      • Laxatives
      • Antiemetics
    • Recent Switch Activity
    • Prescription Products with Anticipated OTC Approvals
      • Proton Pump Inhibitors
        • Protonix
        • Aciphex
      • Mucosal Protectants
      • Antiemetics
  • Market and Competitive Analysis
    • Market Size and Forecast
    • Competitive Analysis

SMOKING CESSATION PRODUCTS

  • Overview
  • Description of Conditions
    • Lung Cancer and Tobacco Use
  • Product Analysis
    • Switched Products
      • Nicotine Chewing Gum
      • Nicotine Transdermal patch
      • Nicotine Oral lozenge
    • Prescription Products with Anticipated OTC Approvals
      • Nicotrol
      • Chantix
    • Market Analysis
      • Market Size and Forecast
      • Competitive Analysis

OTHER DRUG CLASSIFICATIONS

  • Overview
    • Contraceptives
    • Dental Rinses and Fluorides
    • Hair Growth Products
    • Rectal Ointments
    • Sleep Aids
    • Weight Management
  • Description of Conditions
    • Pregnancy
      • Abortion Rates
      • Contraceptive Use
    • Dental carries
    • Hereditary Hair Loss
    • Hemorrhoids
    • Sleeplessness
    • Obesity
    • Urinary Incontinence/Overactive Bladder
  • Conditions with Possible Future OTC Treatments
    • Acne Vulgaris
    • Benign Prostate Hypertrophy (BPH)
    • Elevated Cholesterol
    • Erectile Dysfunction
    • Menopause and Hormone Replacement
    • Menorrhagia
    • Osteoporosis
  • Product Analysis
    • Switched Ingredients
      • Contraceptives
      • Dental rinses and fluoride
      • Hair growth
      • Overactive Bladder
      • Rectal ointments
      • Sleep aids
      • Weight Management
    • Prescription Products with Anticipated OTC Approvals
      • Acne Treatments
      • Cholesterol-reducing Drugs (antilipidemics)
      • Blood Products
    • BPH
    • Erectile Dysfunction
    • Hair Loss Treatment
    • Hormone-Replacement Therapies (HRT)
    • Osteoporosis Treatments
    • Opioid Overdose Treatment
    • Overactive Bladder
    • Sleep Aids
  • Market Analysis
    • Current Market Segments
    • Short-Term New Product Segment Development; 2015-2016
      • Antilipidemics
      • Opioid Overdose Treatment
      • Sexual Dysfunction
    • New Product Segments; Post 2016
      • BPH Treatments
      • Hormone Replacement Therapy and Osteoporosis Treatments
    • Competitive Analysis

TOTAL RX-TO-OTC DRUG MARKET SUMMARY

  • Overview
  • Total market Size and Forecast
  • Switch Forecast in the United States
  • Markets by Segments
  • Competitive Analysis
  • PROFILES FOR MAJOR RX-TO-OTC PARTICIPANTS
  • Introduction
  • Strategies for Continued Product Growth
  • Mergers and Acquisitions
    • GlaxoSmithKline and Novartis AG
    • Bayer AG and Merck & Co.
    • Prestige Brands and Insight Pharmaceuticals
    • Perrigo Company Acquisitions
    • Procter & Gamble and Teva Pharmaceutical Industries
    • Sanofi and Chattem Consumer
    • Schering-Plough and Merck & Co.
    • Wyeth and Pfizer
    • Reckitt Benckiser and Adams Respiratory Therapeutics
  • Simultaneous Marketing - Prescription vs OTC
  • Impact on the Prescription Drug Manufacturer
  • Direct-to-Consumer Advertising
  • Patent Expiration
  • Bayer
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Perrigo Company
  • Pfizer
  • Prestige Brands
  • Procter & Gamble
  • Reckitt Benckiser
  • Sanofi/Chattem

TEVA

COMPANY DIRECTORY

LIST OF EXHIBITS

EXECUTIVE SUMMARY

  • Table 1-1 The U.S. Market for Rx-to-OTC Switches 2009-2019
  • Figure 1-1 The U.S. Market for Rx-to-OTC Switches, 2009-2019

THE OTC DRUG INDUSTRY

  • Table 2-1 Number of Retail Establishments in the United States and Non-Prescription Medicine Availability, 2012
  • Table 2-2

OTC Drug Retail Sales*, 2000-2014

  • Figure 2-1

OTC Retail Sales, 2000-2014

  • Table 2-3 Rx-to-OTC Switches Approved by the FDA 1976-2014
  • Table 2-3 (continued) Rx-to-OTC Switches Approved by the FDA 1976-2014
  • Figure 2-2 Number of New Rx-to-OTC Switches in the United States, per Year 1976-2014
  • Table 2-4 Statistics for Selected Rx-to-OTC Switches (United States)
  • Table 2-5 Estimated OTC Sales by Product Type and Percent of Sales Attributed to Rx-to-OTC Switched Ingredients
  • Figure 2-3 Estimated OTC Sales by Product Type and Percent of Sales Attributed to Rx-to-OTC Switched Ingredients
  • Figure 2-4 Typical Pharmacist-Consumer OTC Drug Counseling Session
  • Figure 2-5 Internet Users, Percent of Total Population, 2014
  • Table 2-6 The U.S. Population, 1980-2050
  • Figure 2-6 The U.S. Population, 1980-2050
  • Table 2-7 Percent U.S. Population Over Age 65 by Year, 2000-2050
  • Figure 2-7 United States Population Trend Age 65+, 2000-2050
  • Table 2-8 U.S. Healthcare Industry Inflation Rates Healthcare Industry Consumer Price Index Comparisons 2000-2014 Data
  • Figure 2-8 U.S. Healthcare Industry Inflation Rates Healthcare Industry Consumer Price Index Comparisons 2000-2010
  • Table 2-9 Legal Classification Status of Selected Ingredients Worldwide
  • Table 2-9 (continued) Legal Classification Status of Selected Ingredients Worldwide (continued)
  • Table 2-9 (continued) Legal Classification Status of Selected Ingredients Worldwide (continued)
  • Table 2-10 Individual Ingredients Switched from Rx to OTC by Country, 2013/2014

ALLERGY, COUGH, COLD, AND SINUS PRODUCTS

  • Figure 3-1 U.S. Incidence of Allergy, Cough, Cold, Sinus Conditions, Superimposed on Total Population, 2014 Estimate
  • Table 3-1 Allergy, Cough, Cold, Sinus Product Ingredients Transferred from Rx-to-OTC Status. 54
  • Table 3-1 (continued) Allergy, Cough, Cold, Sinus Product Ingredients Transferred from Rx-to-OTC Status. 55
  • Figure 3-2 Allergy, Cough, Cold, Sinus Product Ingredients Transferred from Rx-to-OTC by Year56
  • Table 3-2 Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 3-3 The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and Sinus Product Revenues 2009-2019
  • Figure 3-3 The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and Sinus Product Revenues 2009-2019
  • Figure 3-4 The U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, by Percent and Product Type, 2014
  • Figure 3-5 U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, Sinus, Value Switched Brands vs. Switched Equivalents (Generics), 2009-2019
  • Table 3-4 Leading Suppliers' Shares for U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, 2014
  • Figure 3-6 Leading Suppliers' Shares for U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, 2014

ANALGESICS AND OTHER PAIN RELIEVERS

  • Figure 4-1 U.S. Incidence of Conditions with Pain and Inflammatory Symptoms Superimposed on Total Population, 2014 Estimates
  • Table 4-1 Analgesics, NSAIDs and Other Ingredients Transferred from Rx-to-OTC Status
  • Figure 4-2 Analgesics, NSAIDs and Other Ingredients Transferred from Rx-to-OTC by Year
  • Table 4-2 Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 4-3 The U.S. Market for Rx-to-OTC Switches Analgesic Product Revenues 2009-2019
  • Figure 4-3 The U.S. Market for Rx-to-OTC Switches Analgesic Product Revenues 2009-2019
  • Figure 4-4 The U.S. Market for Rx-to-OTC Switches: Analgesic Product Percent by Type, 2014 93
  • Table 4-4 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switches Analgesics 2014
  • Figure 4-6 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switches Analgesics 2014

ANTI-INFECTIVES

  • Figure 5-1 U.S. Incidence of Infections by Type Superimposed on Total Population, 2014 Estimates
  • Table 5-1 Anti-infectives Ingredients Transferred from Rx-to-OTC Status
  • Figure 5-2 Anti-infectives Ingredients Transferred from Rx-to-OTC by Year
  • Table 5-2 Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 5-3 The U.S. Market for Rx-to-OTC Switches Anti-infective Product Revenues 2009-2019116
  • Figure 5-3 The U.S. Market for Rx-to-OTC Switches Anti-infective Product Revenues 2009-2019117
  • Figure 5-4 The U.S. Market for Rx-to-OTC Switches: Anti-infective Product Type, 2014
  • Table 5-4 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switched Anti-infectives 2014
  • Figure 5-6 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switched Anti-infectives 2014

GASTROINTESTINAL DRUGS

  • Figure 6-1 U.S. Incidence of Gastrointestinal Conditions and Disorders Superimposed on Total Population, 2014 Estimate
  • Table 6-1 Gastrointestinal Drug Ingredients Transferred from Rx-to-OTC Status
  • Figure 6-2 Gastrointestinal Drug Ingredients Transferred from Rx-to-OTC by Year
  • Table 6-2 Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 6-3 The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drug Revenues 2009-2019139
  • Figure 6-3 The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drug Revenues 2009-2019140
  • Figure 6-4 The U.S. Market for Rx-to-OTC Switches: Gastrointestinal Drug by Product Type, 2014141
  • Table 6-4 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs 2014
  • Figure 6-6 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs 2014

SMOKING CESSATION PRODUCTS

  • Table 7-1 Smoking Cessation Product Ingredients Transferred from Rx-to-OTC Status
  • Figure 7-1 Smoking Cessation Product Ingredients Transferred from Rx-to-OTC by Year
  • Table 7-2 Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 7-3 The U.S. Market for Rx-to-OTC Switches Smoking Cessation Product Revenues 2009- 2019
  • Figure 7-2 The U.S. Market for Rx-to-OTC Switches Smoking Cessation Product Revenues 2009- 2019
  • Figure 7-3 The U.S. Market for Rx-to-OTC Switches: Smoking Cessation Product Type, 2014 . 160
  • Table 7-4 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs 2014
  • Figure 7-5 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs 2014

OTHER DRUG CLASSIFICATIONS

  • Table 8-1 U.S. Crude Birth Rate per 1,000 Persons 2000, 2005, 2010 and Projected 2015 and 2020170
  • Table 8-2 Miscellaneous Drug Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
  • Figure 8-1 Miscellaneous Drug Ingredients Transferred from Rx-to-OTC by Year
  • Table 8-3 Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 8-3 (continued) Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 8-4 The U.S. Market for Rx-to-OTC Switches Other Drug Classification Product Revenues 2009-2019
  • Figure 8-2 The U.S. Market for Rx-to-OTC Switches Other Drug Classification Product Revenues 2009-2019
  • Figure 8-3 The U.S. Market for Rx-to-OTC Switches Other Drug Classifications Distribution of Revenues by Product Type 2014
  • Figure 8-4 The U.S. Market for Rx-to-OTC Switches Other Drug Classifications Distribution of Revenues by Product Type 2019

TOTAL RX-TO-OTC DRUG MARKET SUMMARY

  • Table 9-1 The U.S. Market for Rx-to-OTC Switches 2009-2019
  • Figure 9-1 The U.S. Market for Rx-to-OTC Switches, 2009-2019
  • Table 9-2 Potential Rx-to-OTC Switches, 2015-2019
  • Table 9-2 (continued) Potential Rx-to-OTC Switches, 2015-2019
  • Table 9-2 (continued) Potential Rx-to-OTC Switches, 2015-2019
  • Table 9-3 The U.S. Market for Rx-to-OTC Switches 2009-2019
  • Figure 9-2 The U.S. Market for Rx-to-OTC Switches by Product Category, 2009-2019
  • Figure 9-3 The U.S. Market for Rx-to-OTC Switches, Distribution of Revenues by Product Category 2014
  • Figure 9-4 The U.S. Market for Rx-to-OTC Switches, Distribution of Revenues by Product Category 2019
  • Table 9-4 Leading Suppliers Significant Segments of Participation within the U.S. Market for Rxto-

OTC Switches, 2014

  • Figure 9-5 Leading Suppliers Market Share in the U.S. Market for Rx-to-OTC Switches, 2014 .. 229

PROFILES FOR MAJOR RX-TO-OTC PARTICIPANTS

COMPANY DIRECTORY

Back to Top